朗迪Reneed品牌怎么样 申请店铺

我要投票 朗迪Reneed在补钙行业中的票数:865 更新时间:2026-02-17
朗迪Reneed是哪个国家的品牌?「朗迪Reneed」是 北京振东康远制药有限公司 旗下著名品牌。该品牌发源于北京市,由创始人李昆在2003-11-07期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力朗迪Reneed品牌出海!将品牌入驻外推网,定制朗迪Reneed品牌推广信息,可以显著提高朗迪Reneed产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

朗迪Reneed怎么样

钙营养补充剂品牌,主打维生素矿物质钙补充剂类药物,集研发、生产、销售于一体的集团化现代综合制药企业


北京振东康远制药有限公司始建于2003年10月,是国内较大的具有自主品牌的维生素矿物质钙补充剂类药物生产企业,是一家集研发、生产、销售于一体的集团化现代综合制药公司,是中国补钙药物的佼佼者和先锋。公司产品遍布全国,公司“朗迪”牌碳酸钙D3片(II)和碳酸钙D3颗粒已成为中国钙补充剂类药品市场的主流。公司2015年与上市公司振东集团山西振东制药股份有限公司强强联合,完成重大重组,实现了跨跃式发展。

公司于2009年进入中国钙制剂市场,旗下现有7家直属或控股的制药公司、2家直属药物研发公司及多家医药贸易公司,在30多个城市设立了办事机构,有数千家合作伙伴,累计总投资超过10亿元,全国有数千名员工为康远工作。

公司位于北京市昌平区西部约15公里的北京市昌平区流村工业园内,隶属中关村科技园昌平园。该厂区自2012年开始建造,总投资近亿元,按照新版欧盟GMP标准及中国GMP标准进行规划、设计和建设施工,配有国际前沿的制粒、干燥、混合、压片、包装等片剂、硬胶囊剂、颗粒剂生产线及软胶囊剂生产线,该项目已于2014年通过了BFDA组织的GMP认证,并获得片剂、硬胶囊剂、颗粒剂、软胶囊剂GMP证书。项目年生产能力近百亿片(粒、袋)。该项目的建成使康远制药一跃成为国内维生素矿物质钙补充剂类药物较大生产企业。

公司发展过程中始终以“构建国人健康骨骼”为已任,以“树民族工业品牌,为中国制药争光”为使命,为中国钙制剂的发展做出了较大的贡献,大大改善了亿万国人的生活质量。康远人负有共同的使命,遵循一致的价值观,始终秉承“济世安康、立勋鸿远”宗旨来服务社会、回报社会。目前公司年营业收入达数十亿元,年上缴税金数亿元。随着公司高速发展和对未来中国经济和全球钙制剂市场发展前景充分信心,北京振东康远制药正不断加快创新、运筹帷幄、酝酿百年规划,未来的康远终将成为一家拥有精良技术和设备、管理成熟的世界制药公司。


Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd., a brand of calcium supplements, is a group modern comprehensive pharmaceutical enterprise integrating R & D, production and sales. It was founded in October 2003. It is a large domestic manufacturer of vitamin and mineral calcium supplements with its own brand, integrating R & D, production and sales Group modern comprehensive pharmaceutical company is the leader and pioneer of calcium supplements in China. The company's products are all over the country, and its "landi" brand calcium carbonate D3 tablets (II) and calcium carbonate D3 particles have become the mainstream of China's calcium supplements market. In 2015, the company and the listed company Zhendong Group Shanxi Zhendong Pharmaceutical Co., Ltd. jointly completed major restructuring and achieved a leap forward development. In 2009, the company entered the calcium preparation market in China. At present, it has 7 pharmaceutical companies directly under or controlled by the company, 2 pharmaceutical research and development companies directly under the company and many pharmaceutical trading companies. It has set up offices in more than 30 cities, thousands of partners, with a total investment of more than 1 billion yuan, and thousands of employees working for Kangyuan. The company is located in Liucun Industrial Park, Changping District, Beijing, about 15km away from the west of Changping District, Beijing. The plant has been constructed since 2012, with a total investment of nearly 100 million yuan. It is planned, designed and constructed in accordance with the new version of EU GMP standard and China GMP standard. It is equipped with internationally cutting-edge tablet, hard capsule, granule production line and soft capsule production line. The project has passed the GMP certification organized by bfda in 2014, and has obtained tablet GMP certificate of hard capsule, granule and soft capsule. The annual production capacity of the project is nearly 10 billion pieces (grain and bag). With the completion of the project, Kangyuan pharmaceutical has become a large domestic manufacturer of vitamin, mineral and calcium supplements. In the development process of the company, we always take "building healthy skeleton of Chinese people" as our responsibility, take "building national industrial brand, winning honor for Chinese pharmaceutical" as our mission, and have made great contribution to the development of Chinese calcium preparation, greatly improving the quality of life of hundreds of millions of Chinese people. Kangyuan people have a common mission, follow the same values, and always adhere to the tenet of "helping the world and health, and making contributions to Hongyuan" to serve and repay the society. At present, the company's annual operating revenue is billions of yuan, and the annual tax payment is hundreds of millions of yuan. With the rapid development of the company and full confidence in the future development of China's economy and the global calcium preparation market, Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd. is constantly accelerating innovation, strategizing and brewing a hundred year plan. In the future, Kangyuan will eventually become a world pharmaceutical company with excellent technology and equipment and well managed.

本文链接: https://brand.waitui.com/52bc17e3b.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

联合利华与谷歌云达成五年合作

联合利华与谷歌云达成五年合作,将使用谷歌云的先进人工智能、数据及平台服务。(新浪财经)

2小时前

今起对加拿大英国持普通护照者免签

为进一步便利中外人员往来,今天(2月17日)起,我国对加拿大、英国持普通护照人员实施免签政策。两国持普通护照人员来华经商、旅游观光、探亲访友、交流访问、过境不超过30天,可免办签证入境。相关免签政策实施至今年12月31日。(CCTV国际时讯)

2小时前

春节假期前两天,绿色、智能、健康类消费需求旺盛

商务大数据显示,假期前两天,全国重点零售和餐饮企业日均销售额较2025年春节前两天增长10.6%。2月15日,商务部重点监测的78个步行街(商圈)客流量、营业额比去年假期第一天分别增长23.2%、33.2%。以旧换新充分释放消费需求。截至2月16日,2026年消费品以旧换新惠及2755.6万人次,带动销售额1930.9亿元。其中,汽车以旧换新60.7万辆,带动新车销售额995.6亿元。绿色、智能、健康消费需求旺盛。商务大数据显示,2月15日,重点平台智能穿戴设备销售额增长1.3倍,智能血压仪、血糖仪增长超60%,有机食品增长52%。(央视新闻)

2小时前

阿达尼计划投资千亿美元建数据中心

阿达尼集团计划至2035年投资1000亿美元,开发由绿色能源驱动的人工智能数据中心,显示亿万富翁Gautam Adani旨在抓住印度作为人工智能与云计算中心崛起的机遇。集团旗舰企业阿达尼企业有限公司在周二的公告中表示,这笔投资可能在未来十年“催化”额外1500亿美元投入,涵盖服务器制造、先进电力基础设施及相关行业。(新浪财经)

2小时前

华纳兄弟考虑重启收购谈判,派拉蒙股价走高

据报道,在哥伦比亚广播公司母公司派拉蒙修改报价后,华纳兄弟探索公司正考虑重启收购谈判,受此消息影响,派拉蒙天舞公司股价在盘前交易中上涨2.8%。知情人士透露,华纳兄弟董事会成员正在讨论派拉蒙是否能给出更优方案,此举可能再度引发与奈飞的竞购战。奈飞股价在盘前交易中下跌0.5%,华纳兄弟股价上涨0.9%。(新浪财经)

2小时前

本页详细列出关于朗迪Reneed的品牌信息,含品牌所属公司介绍,朗迪Reneed所处行业的品牌地位及优势。
咨询